Pulmonary arterial hypertension in scleroderma: care gaps in screening

One in six patients with systemic sclerosis will develop pulmonary arterial hypertension (PAH). Screening with echocardiography and possibly pulmonary function testing (to determine the diffusing capacity of carbon monoxide) is recommended to detect PAH at a less severe stage. However, real-world sc...

Descripción completa

Detalles Bibliográficos
Autor principal: Pope, Janet E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461777/
https://www.ncbi.nlm.nih.gov/pubmed/28587630
http://dx.doi.org/10.1186/s13075-017-1347-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461777/
https://www.ncbi.nlm.nih.gov/pubmed/28587630
http://dx.doi.org/10.1186/s13075-017-1347-4

Ejemplares similares